title: Large granular lymphocytes from B-chronic lymphocytic leukemia patients inhibit normal B cell proliferation.
abstract: Large granular lymphocytes (LGL) may exert regulatory influences on B cell immunoglobulin synthesis. We, therefore, investigated the influence of LGL from controls and B cell chronic lymphocytic leukemia patients (B-CLL) on control B cell proliferation to costimulation with the F(ab')2 fragment of goat antihuman mu and B cell growth factor (BCGF). Purified LGL (greater than 90% by morphology) from control and B-CLL peripheral blood were added in various concentrations to purified control B cells and incubated with anti-mu and BCGF for 3 days. [3H]-thymidine uptake of B cells was then measured. There was no proliferation of control or CLL LGL alone to the costimulatory signals of the F(ab')2 fragments of goat antihuman mu chain and BCGF. Addition of control LGL to equal numbers of control B cells did not blunt control B cell responsiveness to BCGF (with control LGL 8,649 +/- 298 cpm vs. control B cells alone 8,336 +/- 556 cpm, mean +/- SEM). When control LGL were increased to 10:1 LGL:B cell ratio, the maximal inhibition by control LGL of control B cell proliferative response to BCGF was 23%. In contrast, addition of CLL LGL at a 1:1 LGL:B cell ratio resulted in marked impairment of the control B cell proliferative response to BCGF (with CLL LGL 3,586 +/- 954 cpm vs. control B cells alone 8,649 +/- 298 cpm). Inhibition by CLL LGL occurred in a cell-concentration-dependent manner. No difference in CLL LGL's inhibitory effect on either resting or activated control B cell responsiveness to BCGF was noted. Inhibition of de novo protein synthesis (by cycloheximide inhibition) of CLL LGL did impair CLL LGL's inhibitory capacity for BCGF-induced B cell proliferation. A possible explanation for these findings includes the possibility that a subgroup of LGL with B cell suppressive activity may have expanded as a host response to the B cell leukemia or as part of the disordered cell regulation in B-CLL.
authors.affiliation: Department of Medicine, Veterans Administration Medical Center, Minneapolis, Minnesota 55417.
authors.forename: R T
authors.initials: RT
authors.lastname: Perri
authors.forename: N E
authors.initials: NE
authors.lastname: Kay
mesh_terms: D000361:Agammaglobulinemia / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000166:cytology* / Q000276:immunology; D001696:Biomechanical Phenomena; D002455:Cell Division; D006098:Granulocytes / Q000473:pathology / Q000502:physiology*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000502:physiology; D007148:Immunoglobulin mu-Chains / Q000502:physiology; D015847:Interleukin-4; D007378:Interleukins / Q000502:physiology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology*; D008214:Lymphocytes / Q000473:pathology / Q000502:physiology*; D008875:Middle Aged; D012016:Reference Values
chemical_list: D007140:Immunoglobulin Fab Fragments; D007148:Immunoglobulin mu-Chains; D007378:Interleukins; D015847:Interleukin-4